https://www.selleckchem.com/pr....oducts/semaxanib-su5
atients at highest risk, particularly young patients and lower resourced families, should be prioritized.The author should give careful consideration to the study eligibility criteria of systematic reviews (SRs) and follow it after review protocol development to reduce the possibility of manipulation of inclusion. Our aim was to investigate the prevalence of differences in study eligibility criteria between non-Cochrane SRs and their pre-registered protocols on PROSPERO, and determined what changes were involved as well as whet
Like
Comment
Share
